How Immutep’s Efti Combo Achieved 51.5% Tumor Response in Soft Tissue Sarcoma

middle.news 8:25am on Monday 20th of October, 2025 AEDT • Healthcare Read Story

How Immutep’s Efti Combo Achieved 51.5% Tumor Response in Soft Tissue Sarcoma

8:25am on Monday 20th of October, 2025 AEDT Key Points Phase II EFTISARC-NEO trial met primary endpoint with 51.5% tumor hyalinization Tumor response over three times higher than standard radiotherapy alone Efti combined with KEYTRUDA and radiotherapy showed strong safety profile Results consistent across multiple soft tissue sarcoma subtypes Read Story

middle. Tap to Read Tap the card to read the full analysis about IMM OPEN ARTICLE